MarginsXMarginsX
Home › Markets › Health Care › GPCR

Structure Therapeutics Inc. (GPCR)

GPCR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$18.57
-7.15% on the day
Market cap
$1.3B
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerGPCR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2023
SEC CIK0001888886
SEC industry codePharmaceutical Preparations
Incorporated inCayman Islands

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
9.8 months
$222.0M cash at September 30, 2026
Share count, 1 year
+18.0%
2025-10-31 to 2026-10-31 · +54.3% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$222.0M cash; operating cash flow -$67.7M a quarter.Report 2026-09-30
Shares outstanding71,590,355 (2026-10-31); 60,677,640 a year earlier; 46,386,438 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-05-07
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$144.8M-$101.7M$222.0MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$106.2M-$120.1M$272.6MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2026
2026-03-31
Not filed-$76.0M$15.2M$316.2MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
Not filed$33.0M-$64.4M$799.6MNo debt tagsNeeds four quarters10-K 2026-02-26
Q3 2025
2025-09-30
Not filed-$65.7M-$51.0M$102.9MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2025
2025-06-30
Not filed-$61.7M-$54.6M$147.0MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2025
2025-03-31
Not filed-$46.8M-$52.2M$152.1MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2024
2024-12-31
Not filed-$36.5M-$36.5M$169.5MNo debt tagsNeeds four quarters10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-07
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-09
Latest current report
FORM 8-K
8-K2026-11-09
Latest proxyDEF 14A2026-04-23

Source: SEC EDGAR submissions feed, 275 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.7%
1 month-10.4%
3 months-63.4%
Year to date-71.2%
1 year-42.9%
From 52-week high-78.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AVLNAvalyn Pharma Inc.$29.76-1.72%$1.3B
OCULOcular Therapeutix Inc.$6.01-3.22%$1.3B
INVAInnoviva Inc.$18.49-2.84%$1.3B
GENBGenerate Biomedicines Inc.$10.49-13.09%$1.4B
NUVBNuvation Bio Inc.$3.84-3.76%$1.4B
ANABAnaptysBio Inc.$45.73-1.12%$1.4B
TYRATyra Biosciences Inc.$19.74-1.42%$1.4B
MLYSMineralys Therapeutics Inc.$14.53-5.22%$1.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier